The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies
about
Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosisFunctional structure of the somatomedin B domain of vitronectinMouse aortic ring assay: A new approach of the molecular genetics of angiogenesisPlasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic TestingMaspin inhibits cell migration in the absence of protease inhibitory activitybcn-1 Element-dependent activation of the laminin gamma 1 chain gene by the cooperative action of transcription factor E3 (TFE3) and Smad proteinsThe solution structure of the N-terminal domain of human vitronectin: proximal sites that regulate fibrinolysis and cell migrationThe Kunitz-like modulatory protein haemangin is vital for hard tick blood-feeding successTransient reduction of placental angiogenesis in PAI-1-deficient miceTranscriptional corepressors HIPK1 and HIPK2 control angiogenesis via TGF-β-TAK1-dependent mechanismA genetic expression profile associated with oral cancer identifies a group of patients at high risk of poor survival.Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell lines.Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type I.uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer.PAI-1 Regulates the Invasive Phenotype in Human Cutaneous Squamous Cell Carcinoma.Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycleVitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells.Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment.Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer.Plasminogen activator inhibitor-1 and the kidney.Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.Pleiotropic functions of plasminogen activator inhibitor-1.Proteins and carbohydrates in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy.Tissue plasminogen activator and plasminogen activator inhibitor 1 contribute to sonic hedgehog-induced in vitro cerebral angiogenesis.Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditionsCellular strategies for proteolytic targeting during migration and invasion.The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment.Emerging multifunctional aspects of cellular serine proteinase inhibitors in tumor progression and tissue regeneration.SERPINE1 (PAI-1) is a prominent member of the early G0 --> G1 transition "wound repair" transcriptome in p53 mutant human keratinocytes.Genomic approach to identify factors that drive the formation of three-dimensional structures by EA.hy926 endothelial cells.Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner.Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-αVβ3 integrin cross talk.SERPINE1 (PAI-1) is deposited into keratinocyte migration "trails" and required for optimal monolayer wound repairUnimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor.Proteases, extracellular matrix, and cancer: a workshop of the path B study sectionIMD-4690, a novel specific inhibitor for plasminogen activator inhibitor-1, reduces allergic airway remodeling in a mouse model of chronic asthma via regulating angiogenesis and remodeling-related mediatorsMolecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.Membrane associated proteases and their inhibitors in tumour angiogenesis.Plasminogen activator inhibitor 1 (PAI-1): in vitro activities and clinical relevance.Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity.
P2860
Q24319106-2AD8E060-C371-40B7-9BA7-0EFF73F2E49BQ24648799-4FB86FFC-477C-4F58-9468-CABF2FD7E3D1Q24797401-F9F4A481-A48E-4B62-9429-8D6118CF1F38Q26801060-7779DA62-C495-4FDB-98FE-83ABA74EAB3AQ28207990-9E8788D6-4B17-4D9D-A2E1-F837189CE286Q28216002-BB32A088-71D7-4F32-B93D-E2BA085C07A5Q28259956-50D46F4A-75AC-425E-BCF7-F02B8FD250EFQ28475701-BD584B08-4894-4D7D-97C3-1F84FDB20B41Q28510418-62F482F5-3CA9-4C7E-91FD-F22C14BFDA0AQ28585338-01D4115D-C672-4718-9A46-4EE2C16C0541Q30487675-12EA90BE-6D31-4A15-BF01-4E4C94FA50CFQ33292446-7774D59F-A892-46B8-BFB7-4C32C723779EQ33295022-DCAC9B01-DB3E-4224-BDE2-4A2613085B4DQ33376876-375D95C3-4CC1-48BA-BC5A-07DF19511F49Q33693105-B934467B-D777-4D00-9B62-7F902F084A96Q33715393-E7811F4F-29B8-4F2B-A941-DB2B511457FAQ33728338-536504D7-E61E-43EA-93C6-2E2AABE1EC09Q33812093-ACD667C3-F86C-40CE-B28D-3B3C995DEB50Q33867384-9079CBB8-C457-4F53-9B15-A4CA38AAE503Q33960082-317D9729-EEB5-4E78-B6ED-1D679E960036Q33962566-F3577526-70FF-49DE-A50E-5F885C4A4419Q33984228-3E69AC08-B5FE-44D6-9E3C-FCBB3FCAC7FAQ34148127-D229D0F4-4B20-4AE0-A73C-383C0D6B2053Q34202920-F9B03BBF-7251-4332-9AF1-A6FB747BBA6FQ34217461-8B7677DB-E2EE-40D1-84F3-75D5DE6D687EQ34395533-4F5C8D94-AB90-4DEF-A917-81E32D4E70CFQ34584787-79882668-C575-44FC-B3F2-BC2F3DE7B165Q34592412-531AB42F-CE54-4097-B1CB-29DA2B3B979AQ34691253-03694424-FB52-4262-BB61-DA925C323B86Q34723357-03733B28-791D-4710-B0DA-439A4112EF9AQ34725029-E0124318-AEE4-4D73-A472-11339E207478Q34735474-47CB4F28-DAC4-4A13-AE8C-B0796CADCEA9Q34767246-EA93228B-776A-4313-941D-B0FF30081040Q34887726-599449C6-F95B-46F8-88A0-93B9F07CE9E8Q35097428-57F7AE34-DBC2-4FD1-8F80-D5F903A18F59Q35191973-350ABCA8-18F4-4FE3-9C1B-BE6C5654176DQ35219000-580EB1AF-BF66-40C3-AA0E-4573D5251C3EQ35587684-BD1BDE96-64B5-42E9-9B20-EB8988ADC3AEQ35688843-2F81C28F-01D8-4033-A554-726340AE86BEQ35711136-BF70ED8D-5279-4CAF-87E5-67ED87D08B82
P2860
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
The plasminogen activator inhi ...... for antiangiogenic strategies
@ast
The plasminogen activator inhi ...... for antiangiogenic strategies
@en
The plasminogen activator inhi ...... for antiangiogenic strategies
@nl
type
label
The plasminogen activator inhi ...... for antiangiogenic strategies
@ast
The plasminogen activator inhi ...... for antiangiogenic strategies
@en
The plasminogen activator inhi ...... for antiangiogenic strategies
@nl
prefLabel
The plasminogen activator inhi ...... for antiangiogenic strategies
@ast
The plasminogen activator inhi ...... for antiangiogenic strategies
@en
The plasminogen activator inhi ...... for antiangiogenic strategies
@nl
P2093
P2860
P50
P3181
P356
P1476
The plasminogen activator inhi ...... for antiangiogenic strategies
@en
P2093
D Loskutoff
G Carmeliet
J M Foidart
N E Fusenig
P Carmeliet
P2860
P304
P3181
P356
10.1083/JCB.152.4.777
P407
P577
2001-02-01T00:00:00Z